Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Colorectal Neoplasms

Free Subscription Articles published in Cancer Res Retrieve available abstracts of 68 articles: HTML format

Single Articles

June 2024
1. LI L, Jiang D, Liu H, Guo C, et al
   Comprehensive Proteogenomic Profiling Reveals the Molecular Characteristics of Colorectal Cancer at Distinct Stages of Progression.
   Cancer Res. 2024 Jun 11. doi: 10.1158/0008-5472.CAN-23-1878.
   PubMed     Abstract available
   
   
   May 2024
2. BAKER AM, Nageswaran G, Nenclares P, Ronel T, et al
   FUME-TCRseq Enables Sensitive and Accurate Sequencing of the T-cell Receptor from Limited Input of Degraded RNA.
   Cancer Res. 2024;84:1560-1569.
   PubMed     Abstract available
   
   
   
3. BAHRAMBEIGI V, Lee JJ, Branchi V, Rajapakshe KI, et al
   Transcriptomic Profiling of Plasma Extracellular Vesicles Enables Reliable Annotation of the Cancer-Specific Transcriptome and Molecular Subtype.
   Cancer Res. 2024;84:1719-1732.
   PubMed     Abstract available
   
   
   April 2024
4. YANG S, Zhang D, Sun Q, Nie H, et al
   Single-Cell and Spatial Transcriptome Profiling Identifies the Transcription Factor BHLHE40 as a Driver of EMT in Metastatic Colorectal Cancer.
   Cancer Res. 2024 Apr 24. doi: 10.1158/0008-5472.CAN-23-3264.
   PubMed     Abstract available
   
   
   
5. ZHAO N, Cao Y, Tao R, Zhu X, et al
   The circMYBL2-encoded p185 protein suppresses colorectal cancer progression by inhibiting serine biosynthesis.
   Cancer Res. 2024 Apr 18. doi: 10.1158/0008-5472.CAN-23-2940.
   PubMed     Abstract available
   
   
   
6. CHEN Y, Ying Y, Ma W, Ma H, et al
   Targeting the Epigenetic Reader ENL Inhibits Super-Enhancer-Driven Oncogenic Transcription and Synergizes with BET Inhibition to Suppress Tumor Progression.
   Cancer Res. 2024;84:1237-1251.
   PubMed     Abstract available
   
   
   March 2024
7. MCCOLLUM SE, Shah YM
   Stressing Out Cancer: Chronic Stress Induces Dysbiosis and Enhances Colon Cancer Growth.
   Cancer Res. 2024;84:645-647.
   PubMed     Abstract available
   
   
   
8. FANG L, Zhang L, Wang M, He Y, et al
   Pooled CRISPR Screening Identifies P-Bodies as Repressors of Cancer Epithelial-Mesenchymal Transition.
   Cancer Res. 2024;84:659-674.
   PubMed     Abstract available
   
   
   February 2024
9. LIU X, Wang X, Yang Q, Luo L, et al
   Th17 cells secrete TWEAK to trigger epithelial-mesenchymal transition and promote colorectal cancer liver metastasis.
   Cancer Res. 2024 Feb 9. doi: 10.1158/0008-5472.CAN-23-2123.
   PubMed     Abstract available
   
   
   January 2024
10. ZHANG R, Kang R, Tang D
    Gut microbiome mediates ferroptosis resistance for colorectal cancer development.
    Cancer Res. 2024 Jan 26. doi: 10.1158/0008-5472.CAN-24-0275.
    PubMed     Abstract available
    
    
    
11. CAO Q, Zhao M, Su Y, Liu S, et al
    Chronic stress dampens Lactobacillus johnsonii-mediated tumor suppression to enhance colorectal cancer progression.
    Cancer Res. 2024 Jan 8. doi: 10.1158/0008-5472.CAN-22-3705.
    PubMed     Abstract available
    
    
    
12. MULLER S, Krishnamurty AT
    One Mutation to Rule Them All: Mutant KRAS Controls Tumor Intrinsic and Microenvironment Signaling.
    Cancer Res. 2024;84:6-8.
    PubMed     Abstract available
    
    
    
13. WANG D, Nakayama M, Hong CP, Oshima H, et al
    Gain-of-Function p53 Mutation Acts as a Genetic Switch for TGFbeta Signaling-Induced Epithelial-to-Mesenchymal Transition in Intestinal Tumors.
    Cancer Res. 2024;84:56-68.
    PubMed     Abstract available
    
    
    November 2023
14. RIQUELME E, Howell RM, McAllister F
    Microbial Regulation of Vitamin D Linked to Colorectal Cancer: A Sex Bias.
    Cancer Res. 2023;83:3670-3672.
    PubMed     Abstract available
    
    
    
15. BUSH CO, Perry RJ
    Molecular Mechanism of Fasting-Mimicking Diet in Inhibiting Colorectal Cancer Progression: Implications for Immune Therapy and Metabolic Regulation.
    Cancer Res. 2023;83:3493-3494.
    PubMed     Abstract available
    
    
    
16. LI B, Cai Y, Chen C, Li G, et al
    Genetic Variants That Impact Alternative Polyadenylation in Cancer Represent Candidate Causal Risk Loci.
    Cancer Res. 2023;83:3650-3666.
    PubMed     Abstract available
    
    
    
17. CHEN Z, Zhang G, Ren X, Yao Z, et al
    Cross-talk between Myeloid and B Cells Shapes the Distinct Microenvironments of Primary and Secondary Liver Cancer.
    Cancer Res. 2023;83:3544-3561.
    PubMed     Abstract available
    
    
    October 2023
18. LIU S, Locasale JW
    Delineating a role for methionine metabolism in colorectal cancer.
    Cancer Res. 2023 Oct 17. doi: 10.1158/0008-5472.CAN-23-3169.
    PubMed     Abstract available
    
    
    August 2023
19. ZHENG Y, Zhou R, Cai J, Yang N, et al
    Matrix stiffness triggers lipid metabolic crosstalk between tumor and stromal cells to mediate bevacizumab resistance in colorectal cancer liver metastases.
    Cancer Res. 2023 Aug 23:CAN-23-0025. doi: 10.1158/0008-5472.CAN-23-0025.
    PubMed     Abstract available
    
    
    
20. ZHONG Z, Zhang H, Nan K, Zhong J, et al
    Fasting-mimicking diet drives antitumor immunity against colorectal cancer by reducing IgA-producing cells.
    Cancer Res. 2023 Aug 21:CAN-23-0323. doi: 10.1158/0008-5472.CAN-23-0323.
    PubMed     Abstract available
    
    
    
21. XIE Y, Li P, Sun D, Qi Q, et al
    DNA methylation-based testing in peripheral blood mononuclear cells enables accurate and early detection of colorectal cancer.
    Cancer Res. 2023 Aug 21:CAN-22-3402. doi: 10.1158/0008-5472.CAN-22-3402.
    PubMed     Abstract available
    
    
    
22. TANG J, Wang S, Weng M, Guo Q, et al
    The IGF2BP3-COPS7B axis facilitates mRNA translation to drive colorectal cancer progression.
    Cancer Res. 2023 Aug 10:CAN-23-0557. doi: 10.1158/0008-5472.CAN-23-0557.
    PubMed     Abstract available
    
    
    June 2023
23. WEI M, Huang X, Liao L, Tian Y, et al
    SENP1 decreases RNF168 phase separation to promote DNA damage repair and drug resistance in colon cancer.
    Cancer Res. 2023 Jun 23:CAN-22-4017. doi: 10.1158/0008-5472.CAN-22-4017.
    PubMed     Abstract available
    
    
    
24. JAILKHANI N, Clauser KR, Mak HH, Rickelt S, et al
    Proteomic Profiling of Extracellular Matrix Components from Patient Metastases Identifies Consistently Elevated Proteins for Developing Nanobodies That Target Primary Tumors and Metastases.
    Cancer Res. 2023;83:2052-2065.
    PubMed     Abstract available
    
    
    May 2023
25. AGLAGO EK, Kim AE, Lin Y, Qu C, et al
    A genetic locus within the FMN1/GREM1 gene region interacts with body mass index in colorectal cancer risk.
    Cancer Res. 2023 May 30:CAN-22-3713. doi: 10.1158/0008-5472.CAN-22-3713.
    PubMed     Abstract available
    
    
    
26. HUANG X, Sun T, Wang J, Hong X, et al
    Metformin reprograms tryptophan metabolism to stimulate CD8+ T cell function in colorectal cancer.
    Cancer Res. 2023 May 17:CAN-22-3042. doi: 10.1158/0008-5472.CAN-22-3042.
    PubMed     Abstract available
    
    
    April 2023
27. LI S, Du M, Xu K, Ben S, et al
    A germline variant in the BET1L 3'-UTR confers colorectal cancer susceptibility by reducing miRNA binding and m6A modification.
    Cancer Res. 2023 Apr 28:CAN-22-0065. doi: 10.1158/0008-5472.CAN-22-0065.
    PubMed     Abstract available
    
    
    
28. WATLING CZ, Kelly RK, Murphy N, Gunter M, et al
    Prospective analysis reveals associations between carbohydrate intakes, genetic predictors of short-chain fatty acid synthesis, and colorectal cancer risk.
    Cancer Res. 2023 Apr 25:CAN-22-3755. doi: 10.1158/0008-5472.CAN-22-3755.
    PubMed     Abstract available
    
    
    
29. WOOD CS, Pennel KAF, Leslie H, Legrini A, et al
    Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases.
    Cancer Res. 2023;83:1329-1344.
    PubMed     Abstract available
    
    
    March 2023
30. MILLER AL, Perurena N, Gardner A, Hinoue T, et al
    DAB2IP is a bifunctional tumor suppressor that regulates wildtype RAS and inflammatory cascades in KRAS mutant colon cancer.
    Cancer Res. 2023 Mar 20:CAN-22-0370. doi: 10.1158/0008-5472.CAN-22-0370.
    PubMed     Abstract available
    
    
    December 2022
31. YUE T, Li J, Zhu J, Zuo S, et al
    Hydrogen sulfide creates a favorable immune microenvironment for colon cancer.
    Cancer Res. 2022 Dec 16:CAN-22-1837. doi: 10.1158/0008-5472.CAN-22-1837.
    PubMed     Abstract available
    
    
    
32. ZOU S, Qin B, Yang Z, Wang W, et al
    CSN6 mediates nucleotide metabolism to promote tumor development and chemoresistance in colorectal cancer.
    Cancer Res. 2022 Dec 13:CAN-22-2145. doi: 10.1158/0008-5472.CAN-22-2145.
    PubMed     Abstract available
    
    
    October 2022
33. SANDERS BE, Qiao G, Hirschman J, Meyerson M, et al
    Fusobacterium and Colorectal Cancer: Important Association or Random Coincidence?
    Cancer Res. 2022;82:3671-3672.
    PubMed     Abstract available
    
    
    
34. LOEVENICH LP, Tschurtschenthaler M, Rokavec M, Silva MG, et al
    SMAD4 loss induces c-MYC-mediated NLE1 upregulation to support protein biosynthesis, colorectal cancer growth and metastasis.
    Cancer Res. 2022 Oct 11. pii: 709708. doi: 10.1158/0008-5472.CAN-22-1247.
    PubMed     Abstract available
    
    
    September 2022
35. BOUSTANY LM, LaPorte SL, Wong L, White C, et al
    A Probody(R) T-cell-engaging bispecific antibody targeting EGFR and CD3 inhibits colon cancer growth with limited toxicity.
    Cancer Res. 2022 Sep 16. pii: 709245. doi: 10.1158/0008-5472.CAN-21-2483.
    PubMed     Abstract available
    
    
    
36. FUJISHITA T, Kojima Y, Kajino-Sakamoto R, Mishiro-Sato E, et al
    The cAMP/PKA/CREB and TGF-beta/SMAD4 pathways regulate stemness and metastatic potential in colorectal cancer cells.
    Cancer Res. 2022 Sep 6. pii: 708953. doi: 10.1158/0008-5472.CAN-22-1369.
    PubMed     Abstract available
    
    
    
37. CHEN Y, Yan SM, Pu Z, Feng J, et al
    Dopamine Signaling Promotes Tissue-Resident Memory Differentiation of CD8+ T Cells and Antitumor Immunity.
    Cancer Res. 2022;82:3130-3142.
    PubMed     Abstract available
    
    
    August 2022
38. SOROKIN AV, Kanikarla Marie P, Bitner L, Syed M, et al
    Targeting RAS mutant colorectal cancer with dual inhibition of MEK and CDK4/6.
    Cancer Res. 2022 Aug 1. pii: 707348. doi: 10.1158/0008-5472.CAN-22-0198.
    PubMed     Abstract available
    
    
    May 2022
39. HEINZ MC, Peters NA, Oost KC, Lindeboom RGH, et al
    Liver Colonization by Colorectal Cancer Metastases Requires YAP-Controlled Plasticity at the Micrometastatic Stage.
    Cancer Res. 2022;82:1953-1968.
    PubMed     Abstract available
    
    
    
40. LEBLEU VS
    Plasticity Enables Cooperation among Heterogeneous Cancer Cell Populations to Support Metastatic Fitness.
    Cancer Res. 2022;82:1870-1871.
    PubMed     Abstract available
    
    
    April 2022
41. HSU KS, Adileh M, Martin ML, Makarov V, et al
    Colorectal cancer develops inherent radiosensitivity that can be predicted using patient-derived organoids.
    Cancer Res. 2022 Apr 26. pii: 694761. doi: 10.1158/0008-5472.CAN-21-4128.
    PubMed     Abstract available
    
    
    
42. MONTROSE DC, Galluzzi L
    Restored Ketosis Drives Anticancer Immunity in Colorectal Cancer.
    Cancer Res. 2022;82:1464-1466.
    PubMed     Abstract available
    
    
    
43. ZHANG L, Pickard K, Jenei V, Bullock MD, et al
    Editor's Note: miR-153 Supports Colorectal Cancer Progression via Pleiotropic Effects That Enhance Invasion and Chemotherapeutic Resistance.
    Cancer Res. 2022;82:1669.
    PubMed    
    
    
    
44. MATAS J, Kohrn B, Fredrickson J, Carter K, et al
    Colorectal Cancer Is Associated with the Presence of Cancer Driver Mutations in Normal Colon.
    Cancer Res. 2022;82:1492-1502.
    PubMed     Abstract available
    
    
    
45. MALIER M, Gharzeddine K, Laverriere MH, Marsili S, et al
    Correction: Hypoxia Drives Dihydropyrimidine Dehydrogenase Expression in Macrophages and Confers Chemoresistance in Colorectal Cancer.
    Cancer Res. 2022;82:1436.
    PubMed    
    
    
    
46. ISSA JP
    The Two-Hit Hypothesis Meets Epigenetics.
    Cancer Res. 2022;82:1167-1169.
    PubMed     Abstract available
    
    
    March 2022
47. WEI R, Zhou Y, Li C, Rychahou P, et al
    Ketogenesis attenuates KLF5-dependent production of CXCL12 to overcome the immunosuppressive tumor microenvironment in colorectal cancer.
    Cancer Res. 2022 Mar 3. pii: 681994. doi: 10.1158/0008-5472.CAN-21-2778.
    PubMed     Abstract available
    
    
    January 2022
48. MENG Y, Du M, Gu D, Li C, et al
    Genome-wide association analyses identify CATSPERE as a mediator of colorectal cancer susceptibility and progression.
    Cancer Res. 2022 Jan 24. pii: 0008-5472.CAN-21-2948.
    PubMed     Abstract available
    
    
    December 2021
49. FAN F, Liu P, Bao R, Chen J, et al
    A Dual PI3K/HDAC Inhibitor Induces Immunogenic Ferroptosis to Potentiate Cancer Immune Checkpoint Therapy.
    Cancer Res. 2021;81:6233-6245.
    PubMed     Abstract available
    
    
    November 2021
50. PAIDI SK, Rodriguez Troncoso J, Raj P, Monterroso Diaz P, et al
    Raman Spectroscopy and Machine Learning Reveals Early Tumor Microenvironmental Changes Induced by Immunotherapy.
    Cancer Res. 2021;81:5745-5755.
    PubMed     Abstract available
    
    
    
51. SENDI H, Yazdimamaghani M, Hu M, Sultanpuram N, et al
    Nanoparticle delivery of miR-122 inhibits colorectal cancer liver metastasis.
    Cancer Res. 2021 Nov 9. pii: 0008-5472.CAN-21-2269.
    PubMed     Abstract available
    
    
    
52. COOK DR, Kang M, Martin TD, Galanko JA, et al
    Aberrant expression and subcellular localization of ECT2 drives colorectal cancer progression and growth.
    Cancer Res. 2021 Nov 4. pii: 0008-5472.CAN-20-4218.
    PubMed     Abstract available
    
    
    
53. BERLIN C, Cottard F, Willmann D, Urban S, et al
    KMT9 controls stemness and growth of colorectal cancer.
    Cancer Res. 2021 Nov 4. pii: 0008-5472.CAN-21-1261.
    PubMed     Abstract available
    
    
    
54. KWON M, Rubio G, Nolan N, Auteri P, et al
    FILIP1L Loss Is a Driver of Aggressive Mucinous Colorectal Adenocarcinoma and Mediates Cytokinesis Defects through PFDN1.
    Cancer Res. 2021;81:5523-5539.
    PubMed     Abstract available
    
    
    October 2021
55. GEN Y, Muramatsu T, Inoue J, Inazawa J, et al
    miR-766-5p Targets Super-Enhancers by Downregulating CBP and BRD4.
    Cancer Res. 2021;81:5190-5201.
    PubMed     Abstract available
    
    
    
56. MALIER M, Gharzeddine K, Laverriere MH, Marsili S, et al
    Hypoxia drives dihydropyrimidine dehydrogenase expression in macrophages and confers chemoresistance in colorectal cancer.
    Cancer Res. 2021 Oct 13. pii: 0008-5472.CAN-21-1572.
    PubMed     Abstract available
    
    
    
57. ZHENG X, Liu R, Zhou C, Yu H, et al
    ANGPTL4-mediated promotion of glycolysis facilitates the colonization of Fusobacterium nucleatum in colorectal cancer.
    Cancer Res. 2021 Oct 13. pii: 0008-5472.CAN-21-2273.
    PubMed     Abstract available
    
    
    September 2021
58. NAPOLI M, Deshpande AA, Flores ER
    The Landmark Discovery That Paved the Way to a Mechanistic Understanding of P53 Gain of Function and Personalized Medicine.
    Cancer Res. 2021;81:4394-4396.
    PubMed     Abstract available
    
    
    July 2021
59. WINTER M, Rokavec M, Hermeking H
    14-3-3sigma Functions as an Intestinal Tumor Suppressor.
    Cancer Res. 2021;81:3621-3634.
    PubMed     Abstract available
    
    
    
60. STEINER MC, Marston JL, Iniguez LP, Bendall ML, et al
    Locus-Specific Characterization of Human Endogenous Retrovirus Expression in Prostate, Breast, and Colon Cancers.
    Cancer Res. 2021;81:3449-3460.
    PubMed     Abstract available
    
    
    
61. SAIDA Y, Brender JR, Yamamoto K, Mitchell JB, et al
    Multimodal Molecular Imaging Detects Early Responses to Immune Checkpoint Blockade.
    Cancer Res. 2021;81:3693-3705.
    PubMed     Abstract available
    
    
    June 2021
62. PHILLIPS DC, Buchanan FG, Cheng D, Solomon LR, et al
    Hexavalent TRAIL Fusion Protein Eftozanermin Alfa Optimally Clusters Apoptosis-Inducing TRAIL Receptors to Induce On-Target Antitumor Activity in Solid Tumors.
    Cancer Res. 2021;81:3402-3414.
    PubMed     Abstract available
    
    
    
63. O'CONNELL CE, Vassilev A
    Combined Inhibition of p38MAPK and PIKfyve Synergistically Disrupts Autophagy to Selectively Target Cancer Cells.
    Cancer Res. 2021;81:2903-2917.
    PubMed     Abstract available
    
    
    
64. WANG HQ, Mulford IJ, Sharp F, Liang J, et al
    Inhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal Microenvironment.
    Cancer Res. 2021;81:3079-3091.
    PubMed     Abstract available
    
    
    May 2021
65. BOMMI PV, Bowen CM, Reyes-Uribe L, Wu W, et al
    The Transcriptomic Landscape of Mismatch Repair-Deficient Intestinal Stem Cells.
    Cancer Res. 2021;81:2760-2773.
    PubMed     Abstract available
    
    
    
66. WANG X, Jia Y, Wen L, Mu W, et al
    Porphyromonas gingivalis Promotes Colorectal Carcinoma by Activating the Hematopoietic NLRP3 Inflammasome.
    Cancer Res. 2021;81:2745-2759.
    PubMed     Abstract available
    
    
    
67. FRAU C, Jamard C, Delpouve G, Guardia GDA, et al
    Deciphering the Role of Intestinal Crypt Cell Populations in Resistance to Chemotherapy.
    Cancer Res. 2021;81:2730-2744.
    PubMed     Abstract available
    
    
    
68. YANG B, Li X, Fu Y, Guo E, et al
    MEK Inhibition Remodels the Immune Landscape of Mutant KRAS Tumors to Overcome Resistance to PARP and Immune Checkpoint Inhibitors.
    Cancer Res. 2021;81:2714-2729.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Colorectal Neoplasms is free of charge.